Pharma Leads in a Falling Market — Here’s Why It Matters

Spread love

Indian Pharma Stocks Surge Today: Dr Reddy’s, Cipla, Glenmark & Piramal Rally — Trends, Financials & Technicals

By S. JHA

Mumbai, April 23, 2026 — Indian pharmaceutical stocks outperformed the broader market sharply today, with the Nifty Pharma index emerging as the standout gainer on a day when the Nifty 50 itself slipped into the red. The Nifty Pharma index gained 3 per cent to 23,164.10 in Thursday’s intra-day trade, even as the broader market remained under pressure. The divergence is significant.

Investors are rotating into pharma as a defensive play, drawn by the sector’s relative insulation from global macro volatility and tariff headwinds hitting other cyclical sectors.

Today’s Top Pharma Gainers: Stock-by-Stock Breakdown

Piramal Pharma — Top Gainer of the Day

Piramal Pharma surged 9 per cent to ₹168.50 on the NSE during the day. It settled over 6 per cent higher, making it the top gainer among Nifty Pharma index constituents. The stock has been identified by analysts as a recovery play for the second half of the year. Piramal Pharma operates across multiple pharmaceutical segments, including drug discovery and manufacturing, giving it a diversified revenue base that supports long-term re-rating potential.

Dr Reddy’s Laboratories — Rebound on Semaglutide Watch

Dr Reddy’s shares rose 11 per cent intraday, hitting a day high of ₹1,333 on the NSE. The stock rebounded sharply from last week’s fall as investors closely track the company’s drug approval pipeline. Dr Reddy’s is awaiting approval for its weight-loss drug semaglutide in Brazil and Canada.

On the domestic front, the company is firing on all cylinders. Dr Reddy’s delivered a standout 18.2 per cent monthly growth print in March 2026. Analysts at Nomura note that Dr Reddy’s could gain above-average market share in the semaglutide segment, which is projected to become a ₹12,000 crore market in India over the next five years.

Cipla — Steady Gains, Leadership Transition Underway

Cipla shares rose 4.7 per cent intraday, continuing the stock’s recent positive momentum. From a valuation standpoint, Cipla’s P/E stands at 20.6, well below the industry average of 31.9, suggesting the stock remains attractively priced relative to peers.

Regulatory activity remains a near-term watch point: the USFDA inspected Cipla’s Goa unit from April 6–17, 2026, noting two Form 483 observations, with Cipla committing to address them within the required timeline. Separately, Cipla’s new MD & CEO, Achin Gupta, assumed the top role from April 1, 2026, bringing fresh strategic leadership to one of India’s most recognised pharma brands.

Analyst view: Cipla is categorised as a recovery play, with one analyst recommending it as a buy in the second half of the year alongside Piramal Pharma.

Glenmark Pharmaceuticals — Specialty Focus Drives Confidence

Glenmark Pharmaceuticals rose in the range of 3–6 per cent in today’s intra-day trade. The company’s longer-term investment case is anchored in its speciality portfolio: Glenmark is known for its presence in respiratory, dermatology, and oncology segments, and continues to expand through strategic collaborations and innovation. Its solid research pipeline, international market presence, and focus on emerging therapies make it an attractive choice for investors seeking steady growth and long-term returns.

Macro Tailwinds: What’s Driving Pharma Higher?

The rally isn’t just a one-day event — it reflects a broader, structurally supportive environment for Indian pharma:

IPM Growth Running Hot

The Indian Pharma Market posted monthly growth of 10.7 per cent in March 2026, sustaining four consecutive months of double-digit expansion. Chronic therapies led the outperformance, with the cardiac segment delivering 14.9 per cent monthly growth and retaining its position as the largest therapy area at 13.9 per cent share.

Full-Year Market Size

Indian pharma grew 8.8 per cent in FY26 to ₹2.46 lakh crore, led by cardiac (13.6%) and anti-diabetic (11.3%) segments.

Defensive Safe Haven

In a market rattled by geopolitical concerns and global tariff uncertainty, pharma’s non-discretionary demand profile makes it a natural hedge. Investors appear to be flocking to pharma stocks due to the defensive nature of the industry.

Patent Expiry Opportunity

Analysts note that the global patent expiry cycle could drive increased outsourcing and selective M&A activity by global pharma firms, benefiting Indian contract development and manufacturing organisations (CDMOs).

Financials Snapshot: Q4 FY26 Expectations

Analysts at Systematix expect healthcare firms like Sun Pharma, Cipla, and Dr Reddy’s to show 12 per cent revenue growth but a 14 per cent net earnings decline in Q4 FY26. The earnings dip is not alarming in isolation — it reflects specific headwinds: Dr Reddy’s faces steep declines due to gRevlimid tapering off completely, a one-time tailwind from a high-value generic that has now run its course.

Margin pressure is also a sector-wide theme. Sharp margin contractions were seen in major companies such as Cipla, Piramal Pharma, and Dr Reddy’s, primarily due to an adverse product mix and increased investment in R&D activities. Notably, those R&D investments are setting up the pipeline for future revenue — so near-term margin pain may carry long-term gain.

Technicals: Key Levels to Watch

– Dr Reddy’s has rebounded sharply from its recent lows, with the intraday high of ₹1,333 testing overhead resistance. The key watch is whether the semaglutide regulatory update acts as a fresh catalyst.

– Piramal Pharma, up 9%, is in breakout territory — volume confirmation will determine whether this move sustains.

– Cipla, trading at a P/E discount to the industry, has technical room to re-rate if Q4 results clear the bar.

– Glenmark has been building a steady base; today’s 3–6% move keeps it in the uptrend channel.

– The Nifty Pharma index had earlier hit a 52-week high of 23,540.90 on March 11, 2026 — a level it is now eyeing again as a key technical target.

Analyst Picks & Recommendations

Analysts recommend Sun Pharma for its consistent earnings profile, Divi’s Laboratories for long-term visibility, and Cipla and Piramal Pharma as recovery plays for the second half of 2026. Others prefer Dr Reddy’s and Eris Lifesciences, citing strong domestic franchises and R&D capabilities.

Today’s pharma rally is more than a technical bounce. It reflects a convergence of defensive capital rotation, strong domestic IPM growth, an exciting GLP-1/semaglutide pipeline, and attractive valuations in select names. Dr Reddy’s and Piramal led the charge today, but Cipla’s valuation discount and Glenmark’s specialty pipeline mean the broader sectoral story has legs.

(This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making investment decisions.)